Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 113Breast Neoplasms 113Ovarian Neoplasms 69Triple Negative Breast Neoplasms 56Endometrial Neoplasms 42Fallopian Tube Neoplasms 40Squamous Cell Carcinoma of Head and Neck 39Lung Neoplasms 38Neoplasm Metastasis 35Stomach Neoplasms 28Parkinson Disease 4, Autosomal Dominant Lewy Body 27Neoplasms 27Esophageal Neoplasms 22Esophageal Squamous Cell Carcinoma 21Head and Neck Neoplasms 16Uterine Cervical Neoplasms 15Carcinoma, Ovarian Epithelial 15Carcinoma 15Colorectal Neoplasms 14Carcinoma, Squamous Cell 11Adenocarcinoma 10Small Cell Lung Carcinoma 9Adenocarcinoma Of Esophagus 9Peritoneal Neoplasms 8Oropharyngeal Neoplasms 8Melanoma 8Carcinoma, Transitional Cell 8Urinary Bladder Neoplasms 7Pancreatic Neoplasms 7Mouth Neoplasms 7

Interventions

Docetaxel 2Cisplatin 2130-nm albumin-bound paclitaxel 2taxane 1pembrolizumab 1liposomal doxorubicin 1durvalumab 1cemiplimab 1atezolizumab 1Pemetrexed 1Paclitaxel 1Nivolumab 1Granulocyte-Macrophage Colony-Stimulating Factor 1Biosimilar Pharmaceuticals 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Vaccinia × Paclitaxel × 1 year × Clear all
NCT05281471 2026-03-18

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

Genelux Corporation

Phase 3 Recruiting
186 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Vaccinia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡